Evidence map›Paper›PMID 19583806›Full record

ArticleJournal of cellular and molecular medicine2010

Lysyl oxidase interacts with AGE signalling to modulate collagen synthesis in polycystic ovarian tissue.

Katerina K Papachroni, Christina Piperi, Georgia Levidou, Penelope Korkolopoulou, Leszek Pawelczyk, Evanthia Diamanti-Kandarakis, Athanasios G Papavassiliou

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07764328 (A Randomized, Double-blind, Placebo-controlled Study Evaluating the Impact of Milamend on Quality of Life and Hormonal Health in Women With Self-Reported Symptoms Associated With Polycystic Ovary Syndrome), which is not on this map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07764328 narecruitingnot on this mapstarted 2025, after this paper: background citation

A Randomized, Double-blind, Placebo-controlled Study Evaluating the Impact of Milamend on Quality of Life and Hormonal Health in Women With Self-Reported Symptoms Associated With Polycystic Ovary Syndrome (PCOS)

TypeinterventionalSponsorMila Mend Inc.Ran2025 to 2026Enrolled225ConditionsPolycystic Ovarian Syndrome (PCOS)ArmsA dietary supplement powder for women, Placebo
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 76 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Mechanisms of ovarian aging in women: a review.Journal of ovarian research · 2023
    Review
  18. Review
  19. Lysyl oxidase promotes renal fibrosis via accelerating collagen cross-link driving by β-arrestin/ERK/STAT3 pathway.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Katerina K PapachroniDepartment of Biological Chemistry, Medical School, University of Athens, Athens, Greece.
Christina Piperi
Georgia Levidou
Penelope Korkolopoulou
Leszek Pawelczyk
Evanthia Diamanti-Kandarakis
Athanasios G Papavassiliou
National and Kapodistrian University of Athens · GRPoznan University of Medical Sciences · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Connective tissue components--collagen types I, III and IV--surrounding the ovarian follicles undergo drastic changes during ovulation. Abnormal collagen synthesis and increased volume and density of ovarian stroma characterize the polycystic ovary syndrome (PCOS). During the ovulatory process, collagen synthesis is regulated by prolyl hydroxylase and lysyl oxidase (LOX) activity in ovarian follicles. LOX catalyzes collagen and elastin cross-linking and plays essential role in coordinating the control of ovarian extracellular matrix (ECM) during follicular development. We have recently shown accumulation of advanced glycation end products (AGEs), molecules that stimulate ECM production and abnormal collagen cross-linking, in ovarian tissue. However, the possible link between LOX and AGEs-induced signalling in collagen production and stroma formation in ovarian tissue from PCOS remains elusive. The present study investigates the hypothesis of AGE signalling pathway interaction with LOX gene activity in polycystic ovarian (PCO) tissue. We show an increased distribution and co-localization of LOX, collagen type IV and AGE molecules in the PCO tissue compared to control, as well as augmented expression of AGE signalling mediators/effectors, phospho(p)-ERK, phospho(p)-c-Jun and nuclear factor κB (NF-κB) in pathological tissue. Moreover, we demonstrate binding of AGE-induced transcription factors, NF-κB and activator protein-1 (AP-1) on LOX promoter, indicating a possible involvement of AGEs in LOX gene regulation, which may account for the documented increase in LOX mRNA and protein levels compared to control. These findings suggest that deposition of excess collagen in PCO tissue that induces cystogenesis may, in part, be due to AGE-mediated stimulation of LOX activity.

Indexed as

Signal TransductionAdultCollagen Type IVExtracellular MatrixExtracellular Signal-Regulated MAP KinasesFemaleGlycation End Products, AdvancedHumansNF-kappa BPolycystic Ovary SyndromePromoter Regions, GeneticProtein-Lysine 6-OxidaseProto-Oncogene Proteins c-junTranscription Factor AP-1Young AdultCollagen Type IVExtracellular Signal-Regulated MAP KinasesGlycation End Products, AdvancedNF-kappa BProtein-Lysine 6-OxidaseProto-Oncogene Proteins c-junTranscription Factor AP-1

Identifiers

PMID19583806
PMCPMC3823163
OpenAlexW2015052247

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.